WASHINGTON — A federal proposal to impose new restrictions on a key addiction-treatment medicine has induced an uproar in sure segments of the medical neighborhood. However well being secretary Xavier Becerra appears to be on board.
The brand new Drug Enforcement Administration proposal would require that sufferers obtain an in-person examination earlier than acquiring refills of buprenorphine, a key drug used to deal with opioid use dysfunction. When a public emergency was declared in response to Covid-19, sufferers had been allowed to acquire buprenorphine by way of telemedicine or by way of an in-person go to.
Within the wake of the DEA’s proposal, main dependancy medical doctors have warned that limiting entry to the drug might make the opioid disaster even worse. Becerra, nevertheless, mentioned the brand new proposal strikes an applicable steadiness between security and entry.
commercial
“We’ve been capable of have a great partnership with DEA to get to a spot the place they really feel like they’re nonetheless going to be defending the general public from the unfold of medication, and we really feel we’re going to have the ability to defend those that are attempting to get the medicine they could want,” Becerra mentioned on Tuesday, talking at a STAT occasion.
Whereas the brand new proposal would nonetheless permit medical doctors to prescribe buprenorphine by way of telemedicine, it could require new sufferers to indicate up for an in-person examination inside 30 days in the event that they wish to keep on the drug. Current sufferers who had been initiated by way of telemedicine would have a 180-day grace interval earlier than they, too, are topic to the requirement.
commercial
The proposal has garnered intense pushback from the dependancy drugs neighborhood and even Democratic members of Congress. With over 80,000 People dying every year from opioid overdoses, they warn, any new limitation on dependancy remedy entry might have dire penalties.
Detractors embrace the American Society of Dependancy Drugs, Sen. Ed Markey (D-Mass.), and Rep. Paul Tonko (D-N.Y.).
“At a time when 200 individuals on daily basis are dying due to opioid overdose, we can’t roll again entry to efficient, evidence-based drugs,” Markey instructed STAT in a press release final week.
In a press release accompanying the proposal, Anne Milgram, the DEA administrator, mentioned the company was dedicated to “making certain the protection of sufferers,” including that the DEA is “dedicated to the growth of telemedicine with guardrails that stop on-line overprescribing of managed drugs that may trigger hurt.”
Whereas buprenorphine is itself an opioid, it’s extensively considered as protected — each basically and particularly compared to the medication that folks in search of dependancy remedy would possibly in any other case be utilizing, like heroin or fentanyl.
Current research have proven that the dramatic improve in buprenorphine entry because the onset of the Covid-19 pandemic didn’t lead to the next share of opioid overdoses involving buprenorphine. Roughly 2% of opioid overdoses concerned buprenorphine, based on current information, and nearly all overdoses that concerned buprenorphine additionally concerned different medication. Total, fewer than 1 in 600 opioid overdoses is attributable to buprenorphine alone.
Becerra, notably, took care to level out that the DEA proposal is “open for public remark” — in different phrases, that the brand new regulation might nonetheless change earlier than it’s finalized.
He additionally hinted on the long-simmering pressure between DEA, a legislation enforcement company, and the quite a few public well being businesses that concentrate on drug use and dependancy remedy, together with HHS.
“DEA’s mandate may be very totally different from ours,” Becerra mentioned. “They’ve to fret about defending the general public from the unfold of medication. I wish to hold individuals alive. I would like individuals to get off of these medication. I wish to assist them. I don’t need there to be stigma.”
STAT’s protection of power well being points is supported by a grant from Bloomberg Philanthropies. Our monetary supporters should not concerned in any choices about our journalism.